Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
With a market cap of 139.74B, Pfizer(PFE) trades at $24.30. The stock has a price-to-earnings ratio of 18.31 and currently yields dividends of 7.20%.
During the trading session on 2026-07-02, Pfizer(PFE) shares reached a daily high of $24.57 and a low of $23.94. At a current price of $24.30, the stock is +1.5% higher than the low and still -1.1% under the high.
Trading volume for Pfizer(PFE) stock has reached 51.8M, versus its average volume of 62.57M.
The stock's 52-week range extends from a low of $23.11 to a high of $28.75.
The stock's 52-week range extends from a low of $23.11 to a high of $28.75.
PFE News
Pfizer stock is coming off a difficult five-year stretch, with shareholders facing a material decline. The current valuation checks suggest the shares may now b...
...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...
Analyst ratings
59%
of 29 ratingsMore PFE News
Cboe data shows mixed options sentiment in Pfizer (PFE), with shares down 18c near $23.89. Options volume relatively light with 29k contracts traded and calls l...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...
Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat By Alex Sirois Published Jun 30, 12:15PM EDT Quick Read PFE offers a nearly 7...
Key Points Pfizer's acquisition of Metsera last year opens up some exciting opportunities in the GLP-1 space. It wants to be a leader in obesity therapies. W...
Earlier this month, Pfizer received U.S. FDA approval for expanding IBRANCE (palbociclib) to maintenance treatment of adults with HR+, HER2+ locally advanced or...
Pfizer (PFE) is in focus after investors were hit with mixed oncology news, a planned CFO transition, and fresh questions around its pipeline, all set against t...
Key Points One of Pfizer's promising oncology candidates recently failed a phase 3 study. The drugmaker is also losing its CFO. Despite the challenges, there...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.